Investor Update
Basel, 10 March 2011
Herceptin® approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection
Dear Investor,
Please find attached a press release by Chugai.
Do not hesitate to contact us for any further questions.